Octaplas Pediatric Plasma Replacement Trial

Phase 4CompletedNCT02050841

Octapharma50 enrolled

Overview

The purpose of this study is to investigate the safety, tolerability and efficacy of octaplas in pediatric patients who require replacement of multiple coagulation factors. Replacement of multiple coagulation factors in pediatric patients with acquired deficiencies due to liver disease and/or in pediatric patients requiring cardiac surgery or liver surgery.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Liver Surgery Liver Dysfunction Coagulopathy Cardiac Surgery

Interventions

octaplasBIOLOGICAL

Octaplas S/D Plasma

Eligibility

Sex: ALLMax age: 16 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient requiring liver or cardiac surgery and/or patient with liver dysfunction associated with coagulopathy in whom replacement of multiple coagulation factors is required. 2. Voluntarily given, written and signed informed consent by the patient's legal representative(s) or guardian(s). Children deemed old enough by the Investigator/institution to understand the risks and benefits of the study should also be made aware of the risks/benefits of the study and provide written assent. 3. Male or female patient ≤ 16 years of age. Exclusion Criteria: 1. Patient with known homozygous congenital deficiency of protein S. 2. Patient has a history of hypersensitivity reaction to blood or plasma-derived products or to any excipient of the investigational product. 3. Patient has an already known IgA (Immunoglobulin A) deficiency with documented antibodies against IgA. 4. Patient has a congenital factor deficiency or platelet disorder requiring plasma treatment. 5. Patient is currently participating in another study investigating a new drug product or another interventional clinical study that may impact coagulation factors or has participated during the last three (3) months. 6. Patient received FFP (Fresh Frozen Plasma), FP24 (Plasma frozen within 24 hours of collection) or any other plasma product other than Octaplas within the last 72 hours (cryoprecipitate and albumin are not exclusionary) prior to first Octaplas infusion. 7. Patient is on ECMO (Extracorporeal Membrane Oxygenation) when plasma is ordered by the treating physician for the first infusion episode. 8. Patient is pregnant. 9. Patient is predicted to require massive blood transfusion defined as more than 40 mL per kilogram of all blood products in a 24-hour period 10. Patient is receiving plasma exchange, therapeutic plasma exchange (TPE) or plasmapheresis. 11. Patient is a premature neonate defined as less than 37 weeks gestation. 12. Cardiac surgery patients who develop the need for plasma replacement greater than 72 hours after the end of the associated cardiac surgery and do not have coagulopathy due to hepatic dysfunction.

Locations (4)

Octapharma Research Site

Birmingham, Alabama, United States

Octapharma Research Site

Atlanta, Georgia, United States

Octapharma Research Site

Minneapolis, Minnesota, United States

Octapharma Research Site

St Louis, Missouri, United States

Outcomes

Primary Outcomes

Number of Participants With Adverse Drug Reactions (e.g., Allergic Reactions, TEs, TEEs (Thromboembolic Events) and Hyperfibrinolytic Events)

Time frame: up to 6 days

Monitoring of Clinically Significant Changes in White Blood Cells